GlassScriptPhysician profile
Ashley Albright
NPI 1588139042
$1,817.87
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $843 · 2022: $974.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $498.06 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.17 | 2021-2022 | |
| Boston Scientific Corporation | $201.27 | 2021-2022 | |
| Lilly USA, LLC | $144.47 | 2021-2022 | |
| Abbvie INC. | $135.92 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.16 | 2022 | |
| Virtus Pharmaceuticals LLC | $105.71 | 2021-2022 | |
| Almatica Pharma LLC | $77.19 | 2021-2022 | |
| Amgen INC. | $67.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $66.68 | 2021 | |
| Redhill Biopharma INC. | $56.79 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.60 | 2021 | |
| Vertos Medical, INC. | $39.81 | 2022 | |
| Pfizer INC. | $30.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.56 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $11.72 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Albright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.